Jazz Pharmaceuticals Chief Commercial Officer Samantha Pearce to retire by June 2027

Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals plc, has notified the company of her intent to retire from her role. Her departure will take effect upon the earlier of the selection and appointment of her successor or by June 30, 2027, according to a Form 8-K filed with the U.S. Securities and Exchange Commission on October 6, 2026.

The Dublin-based pharmaceutical company stated that it plans to commence a formal search process to identify Ms. Pearce's successor. The search will consider both internal and external candidates. The filing, dated October 6, 2026, was signed by Neena Patil, Executive Vice President and Chief Legal Officer, on October 9, 2026.

Jazz Pharmaceuticals plc is incorporated in Ireland and lists its ordinary shares, with a nominal value of $0.0001 per share, on the Nasdaq Stock Market LLC under the ticker symbol JAZZ. The company's principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.